HIGHLIGHTS
SUMMARY
The Belgian ibrutinib Real-World Data study (BiRD) was designed to investigate the effectiveness and safety of ibrutinib treatment in real-world clinical practice in patients with CLL, MCL or Waldenström`s macroglobulinemia (WM) in Belgium. The authors report the results for the cohort of patients with CLL from the third interim analysis of the BiRD study. were collected for some patients who began ibrutinib before inclusion and yet continued with ibrutinib therapy; therefore, there was a retrospective/prospective safety data collection period for these patients-defined within the retrospective group as "before . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.